Takao Ohnuma, MD, PhD
- PROFESSOR | Medicine, Hematology and Medical Oncology
- PROFESSOR | Oncological Sciences
MD, Tohoku University Medical School
Residency, Rotating, Lincoln Hospital
Residency, Internal Medicine, Coler Memorial Hospital
Residency, Internal Medicine, Roswell Park Memorial Institute
Fellowship, Medical Oncology, Roswell Park Memorial Institute
Dr. Ohnuma's research laboratory, for a number of years, has focused on carrying out cellular, biochemical and molecular pharmacological investigations of cancer therapeutics. During the past year, two projects have been emphasized, the development of ribozyme strategy against deletion-mutant EGFR in the treatment of human glioblastoma multiforme, and the examination of reovirus as an anticancer agent.
Plasse T, Ohnuma T, Brooks S, Saponara E, Holland J, Biller H. Bleomycin infusion followed by cyclophosphamide, methotrexate and fluorouracil in advanced squamous carcinoma of the head and neck. Cancer 1984; 53: 841-843.
Kobayashi H, Takemura Y, Holland JF, Ohnuma T. Vincristine saturation of cellular binding sites and its cytotoxic activity in human lymphoblastic leukemia cells: Mechanism of inoculum effect. Biochem Pharmacol 1998; 55: 1229-1234.
Wang FS, Kobayashi H, Liang KW, Holland JF, Ohnuma T. Retrovirus-mediated anti-MDR1 ribozymes fully restores chemosensitivity of P-glycoprotein-expressing human lymphoma cells. Hum Gene Ther 1999; 10: 1185-1195.
Kobayashi H, Takemura Y, Wang FS, Oka T, Ohnuma T. Retrovirus-mediated transfer of anti-MDR1 hammerhead ribozymes into multidrug-resistant human leukemia cells: Screening for effective target sites. Int J Cancer 1999; 81: 944-950.
Halatsch ME, Botefur IC, Schmidt U, Holland JF, Ohnuma T. Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA. J Neurosurg 2000; 92: 297-305.